Structure Diversification of Vancomycin Through Peptide-catalyzed, Site-selective Lipidation: a Catalysis-based Approach to Combat Glycopeptide-resistant Pathogens

Overview

Journal J Med Chem

Publisher American Chemical Society

Specialty Chemistry

Date 2015 Feb 12

PMID 25671771

Citations 25

Authors

Sabesan Yoganathan

Scott J Miller

Affiliations

Soon will be listed here.

Abstract

The emergence of antibiotic-resistant infections highlights the need for novel antibiotic leads, perhaps with a broader spectrum of activity. Herein, we disclose a semisynthetic, catalytic approach for structure diversification of vancomycin. We have identified three unique peptide catalysts that exhibit site-selectivity for the lipidation of the aliphatic hydroxyls on vancomycin, generating three new derivatives 9a, 9b, and 9c. Incorporation of lipid chains into the vancomycin scaffold provides promising improvement of its bioactivity against vancomycin-resistant enterococci (Van A and Van B phenotypes of VRE). The MICs for 9a, 9b, and 9c against MRSA and VRE (Van B phenotype) range from 0.12 to 0.25 μg/mL. We have also performed a structure-activity relationship (SAR) study to investigate the effect of lipid chain length at the newly accessible G4-OH derivatization site.

Citing Articles

Carbene-catalyzed chirality-controlled site-selective acylation of saccharides.

Liu Y, Zhong Z, Tang Y, Wang H, Vummaleti S, Peng X Nat Commun. 2025; 16(1):54.

PMID: 39746955 PMC: 11697312. DOI: 10.1038/s41467-024-55282-y.

Advances, opportunities, and challenges in methods for interrogating the structure activity relationships of natural products.

Ancajas C, Oyedele A, Butt C, Walker A Nat Prod Rep. 2024; 41(10):1543-1578.

PMID: 38912779 PMC: 11484176. DOI: 10.1039/d4np00009a.

Vancomycin-Polyguanidino Dendrimer Conjugates Inhibit Growth of Antibiotic-Resistant Gram-Positive and Gram-Negative Bacteria and Eradicate Biofilm-Associated .

Chosy M, Sun J, Rahn H, Liu X, Brcic J, Wender P ACS Infect Dis. 2024; 10(2):384-397.

PMID: 38252999 PMC: 11646489. DOI: 10.1021/acsinfecdis.3c00168.

Vibrational Optical Activity Study of Four Antibiotic (Lipo)glycopeptides: Vancomycin, Oritavancin, Dalbavancin, and Teicoplanin.

Aerts R, Bogaerts J, Johannessen C, Herrebout W ACS Omega. 2022; 7(48):43657-43664.

PMID: 36506196 PMC: 9730478. DOI: 10.1021/acsomega.2c04584.

Recent Advances in the Development of Semisynthetic Glycopeptide Antibiotics: 2014-2022.

van Groesen E, Innocenti P, Martin N ACS Infect Dis. 2022; 8(8):1381-1407.

PMID: 35895325 PMC: 9379927. DOI: 10.1021/acsinfecdis.2c00253.

References

Ge M, Chen Z, Onishi H, Kohler J, Silver L, Kerns R . Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala. Science. 1999; 284(5413):507-11. DOI: 10.1126/science.284.5413.507. View

Nicolaou , Boddy , Brase , Winssinger . Chemistry, Biology, and Medicine of the Glycopeptide Antibiotics. Angew Chem Int Ed Engl. 1999; 38(15):2096-2152. DOI: 10.1002/(sici)1521-3773(19990802)38:15<2096::aid-anie2096>3.0.co;2-f. View

Roy R, Yang P, Kodali S, Xiong Y, Kim R, Griffin P . Direct interaction of a vancomycin derivative with bacterial enzymes involved in cell wall biosynthesis. Chem Biol. 2001; 8(11):1095-106. DOI: 10.1016/s1074-5521(01)00075-8. View

Pootoolal J, Neu J, Wright G . Glycopeptide antibiotic resistance. Annu Rev Pharmacol Toxicol. 2002; 42:381-408. DOI: 10.1146/annurev.pharmtox.42.091601.142813. View

Sculimbrene B, Morgan A, Miller S . Enantiodivergence in small-molecule catalysis of asymmetric phosphorylation: concise total syntheses of the enantiomeric D-myo-inositol-1-phosphate and D-myo-inositol-3-phosphate. J Am Chem Soc. 2002; 124(39):11653-6. DOI: 10.1021/ja027402m. View

Chen L, Walker D, Sun B, Hu Y, Walker S, Kahne D . Vancomycin analogues active against vanA-resistant strains inhibit bacterial transglycosylase without binding substrate. Proc Natl Acad Sci U S A. 2003; 100(10):5658-63. PMC: 156257. DOI: 10.1073/pnas.0931492100. View

Evans J, Fierman M, Miller S, Ellman J . Catalytic enantioselective synthesis of sulfinate esters through the dynamic resolution of tert-butanesulfinyl chloride. J Am Chem Soc. 2004; 126(26):8134-5. DOI: 10.1021/ja047845l. View

Miller S . In search of peptide-based catalysts for asymmetric organic synthesis. Acc Chem Res. 2004; 37(8):601-10. DOI: 10.1021/ar030061c. View

Clardy J, Walsh C . Lessons from natural molecules. Nature. 2004; 432(7019):829-37. DOI: 10.1038/nature03194. View

10.

Kahne D, Leimkuhler C, Lu W, Walsh C . Glycopeptide and lipoglycopeptide antibiotics. Chem Rev. 2005; 105(2):425-48. DOI: 10.1021/cr030103a. View

11.

Higgins D, Chang R, Debabov D, Leung J, Wu T, Krause K . Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2005; 49(3):1127-34. PMC: 549257. DOI: 10.1128/AAC.49.3.1127-1134.2005. View

12.

Baltz R, Miao V, Wrigley S . Natural products to drugs: daptomycin and related lipopeptide antibiotics. Nat Prod Rep. 2005; 22(6):717-41. DOI: 10.1039/b416648p. View

13.

Tiyanont K, Doan T, Lazarus M, Fang X, Rudner D, Walker S . Imaging peptidoglycan biosynthesis in Bacillus subtilis with fluorescent antibiotics. Proc Natl Acad Sci U S A. 2006; 103(29):11033-8. PMC: 1544169. DOI: 10.1073/pnas.0600829103. View

14.

Lewis C, Miller S . Site-selective derivatization and remodeling of erythromycin A by using simple peptide-based chiral catalysts. Angew Chem Int Ed Engl. 2006; 45(34):5616-9. DOI: 10.1002/anie.200601490. View

15.

Griffith B, Krepel C, Fu X, Blanchard S, Ahmed A, Edmiston C . Model for antibiotic optimization via neoglycosylation: synthesis of liponeoglycopeptides active against VRE. J Am Chem Soc. 2007; 129(26):8150-5. DOI: 10.1021/ja068602r. View

16.

Davie E, Mennen S, Xu Y, Miller S . Asymmetric catalysis mediated by synthetic peptides. Chem Rev. 2007; 107(12):5759-812. DOI: 10.1021/cr068377w. View

17.

Nitanai Y, Kikuchi T, Kakoi K, Hanamaki S, Fujisawa I, Aoki K . Crystal structures of the complexes between vancomycin and cell-wall precursor analogs. J Mol Biol. 2008; 385(5):1422-32. DOI: 10.1016/j.jmb.2008.10.026. View

18.

Lunde C, Hartouni S, Janc J, Mammen M, Humphrey P, Benton B . Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob Agents Chemother. 2009; 53(8):3375-83. PMC: 2715647. DOI: 10.1128/AAC.01710-08. View

19.

Li J, Vederas J . Drug discovery and natural products: end of an era or an endless frontier?. Science. 2009; 325(5937):161-5. DOI: 10.1126/science.1168243. View

20.

Fischbach M, Walsh C . Antibiotics for emerging pathogens. Science. 2009; 325(5944):1089-93. PMC: 2802854. DOI: 10.1126/science.1176667. View